Andrew D. Badley

Dr. Badley received his M.D. degree from Dalhousie University in Halifax, Nova Scotia in 1990.  He did Internal Medicine Residency and Clinician Investigator Training in Infectious Diseases at Mayo Clinic, Rochester Minnesota, graduating in 1997.  A dual citizen of the United States and Canada, he oversees a successful basic and translational research laboratory program, treats patients with a variety of infectious diseases occurring as a consequence of being immunosuppressed due to HIV infection or prior receipt of a transplant, in addition to his administrative roles outlined below.

Dr. Badley joined the staff of Ottawa Hospital in Ottawa, Ontario, Canada in 1997.  In 2002, Dr. Badley was recruited back to Mayo Clinic as a consultant in Infectious Diseases at which time he moved his successful research laboratory to Mayo Clinic.  Dr. Badley currently is a Professor of Medicine in the Division of Infectious Diseases. His research has led to >130 peer reviewed publications; he has edited or co-edited 3 books, and has written numerous book chapters. Dr. Badley has been appointed to many national and international scientific advisory committees, most notably the prestigious NIH Directors Recombinant DNA Advisory Committee.  Dr. Badley’s research has ranged from elucidating the most basic scientific concepts to conducting investigator initiated clinical trials designed to complete the circle that links bench to bedside.  These efforts have been recognized by elected membership in the American Society of Clinical Investigators (ASCI), Fellowship in the American College of Physicians (FACP) the Royal College of Physicians and Surgeons of Canada (FRCP(C)), and Infectious Diseases Society of America (FIDSA), awards from the Infectious Diseases Society of America and the Canadian Infectious Diseases Society, an outstanding alumnus award from Dalhousie University, his alma mater, as well as an Outstanding Investigator award from Mayo Clinic.

Dr. Badley’s Research focus investigates the regulation of cell death and cell survival during Infectious Diseases, notably HIV, and how understanding these processes can lead to novel therapeutic strategies to reduce morbidity and mortality. Dr. Badley currently holds 2 R01 awards from the National Institute of Health, is Co-Principle Investigator of the Mayo CTSA award, and holds or has filed several patents related to his work. Dr. Badley is also the Founder, President and Chief Scientific Officer of a company related to his published research (Splissen Pharma) , and is Chief Medical Officer of a second company (Qrativ.bio) devoted to efficiently advancing products from intellectual property into clinical use.  Dr. Badley has held numerous leadership positions within the Mayo Clinic, including being the past Associate Dean of Research, and currently, he is the founder and Director of the Office of Translation to Practice, whose mission is to advance research discoveries into clinically relevant products, to the benefit of patients.